Synlogic is accelerating the expansion and development of its pipeline of Synthetic Biotic medicines using the cell programming platform of organism company, Ginkgo Bioworks.
The agreement sees Ginkgo make an $80 million equity investment in Synlogic.
Synlogic will use Ginkgo’s cell programming platform for building and testing thousands of microbial strains to accelerate progression of early preclinical leads to drug candidates optimized for further clinical development.
“This collaboration significantly enhances Synlogic’s Synthetic Biotic strain optimization capabilities and builds on the successful pilot program we began with Ginkgo in late 2017,” said Aoife Brennan, Synlogic’s President and CEO.
“It enables us to advance high-quality candidate strains into development more efficiently and provides technology and resources that will fuel pipeline expansion as we continue to advance our existing clinical programs.”